BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...Inc. (NASDAQ:UTHR); and IV broad-spectrum LACTB inhibitor taniborbactam (VNRX-5133) for complicated urinary tract infections, from VenatoRx Pharmaceuticals Inc....
BioCentury | Aug 21, 2019
Company News

Management tracks: VenatoRx builds out development team; plus Arbutus, Cadent and Arsenal Capital

...Versant Ventures-backed VenatoRx Pharmaceuticals Inc. (Malvern. Pa.) hired Jennifer Ellis as SVP, quality. She was head of quality...
...partner. He was most recently a partner at Baird. Jonathan Block, Associate Editor Arbutus Biopharma Corp. Cadent Therapeutics Inc. VenatoRx Pharmaceuticals Inc. Arsenal...
BioCentury | Jul 23, 2019
Company News

July 22 Company Quick Takes: Vertex submits NDA for triple combo; plus VenatoRX and Biohaven

...Elexacaftor for CF Triple Combo Regimen" ). VenatoRx partners with U.S. agencies for antibiotic development VenatoRx Pharmaceuticals Inc....
...of riluzole. Jonathan Block, Associate Editor Tezacaftor (VX-661) VNRX-5133 VX-445 Biohaven Pharmaceutical Holding Co. Ltd. U.S. Department of Health and Human Services VenatoRx Pharmaceuticals Inc. Vertex...
BioCentury | Apr 5, 2019
Company News

Management tracks: Zealand taps Alnylam’s Dulac as CEO, plus ICER, Jnana and more

...the boards of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) and Seattle Genetics Inc. (NASDAQ:SGEN). Infectious diseases company VenatoRx Pharmaceuticals Inc....
...biotech team. Chico was VP of equity research at Raymond James. BioCentury Staff Esteve S.A. JMP Securities Oxford BioDynamics plc VenatoRx Pharmaceuticals Inc. Wedbush...
BioCentury | Apr 1, 2019
Emerging Company Profile

Arixa: Breaking resistance with oral beta lactamase inhibitors

...is an inhibitor of class A and C LACTB that is in Phase I testing. VenatoRx Pharmaceuticals Inc.’s...
...New York, N.Y. Entasis Therapeutics Inc. (NASDAQ:ETTX), Waltham, Mass. Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH), Watertown, Mass. VenatoRx Pharmaceuticals Inc....
BioCentury | Sep 28, 2018
Company News

Everest adds another antibiotic to pipeline through VenatoRx deal

...C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) will receive exclusive rights from VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) to develop...
...China for Antibiotic" ). Eravacyline is approved in the U.S. as Xerava to treat cIAIs. VenatoRx Pharmaceuticals Inc....
BioCentury | Sep 25, 2018
Company News

Everest adds another antibiotic to pipeline through VenatoRx deal

...C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) will receive exclusive rights from VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) to develop...
...Eravacyline is approved in the U.S. as Xerava to treat cIAIs. Elizabeth S. Eaton VNRX-5133 CBC Group Everest Medicines Ltd. VenatoRx Pharmaceuticals Inc. Beta...
BioCentury | Aug 13, 2018
Company News

Management tracks: FDA, Allergan

...Ophthalmology company Ocugen Inc. (Malvern, Pa.) hired James Murphy as CFO. He was CFO at VenatoRx Pharmaceuticals Inc....
BioCentury | Apr 27, 2018
Clinical News

VenatoRx reports preclinical data for VNRX-5133 plus cefepime

...beta lactamase (LACTB) inhibitor. VenatoRx Pharmaceuticals Inc., Malvern, Pa. Product: VNRX-5133 Business: Infectious Indication: Treat bacterial infections Mary Romeo cefepime VNRX-5133 VenatoRx Pharmaceuticals Inc. Beta...
BioCentury | Mar 30, 2018
Finance

Bug money

...pipelines of several VC-backed companies whose leads are more traditional small molecule antibiotics. For instance, VenatoRx Pharmaceuticals Inc....
...S.A., Romainville, France Spero Therapeutics Inc. (NASDAQ:SPRO), Cambridge, Mass. SutroVax Inc., South San Francisco, Calif. VenatoRx Pharmaceuticals Inc....
Items per page:
1 - 10 of 13
BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...Inc. (NASDAQ:UTHR); and IV broad-spectrum LACTB inhibitor taniborbactam (VNRX-5133) for complicated urinary tract infections, from VenatoRx Pharmaceuticals Inc....
BioCentury | Aug 21, 2019
Company News

Management tracks: VenatoRx builds out development team; plus Arbutus, Cadent and Arsenal Capital

...Versant Ventures-backed VenatoRx Pharmaceuticals Inc. (Malvern. Pa.) hired Jennifer Ellis as SVP, quality. She was head of quality...
...partner. He was most recently a partner at Baird. Jonathan Block, Associate Editor Arbutus Biopharma Corp. Cadent Therapeutics Inc. VenatoRx Pharmaceuticals Inc. Arsenal...
BioCentury | Jul 23, 2019
Company News

July 22 Company Quick Takes: Vertex submits NDA for triple combo; plus VenatoRX and Biohaven

...Elexacaftor for CF Triple Combo Regimen" ). VenatoRx partners with U.S. agencies for antibiotic development VenatoRx Pharmaceuticals Inc....
...of riluzole. Jonathan Block, Associate Editor Tezacaftor (VX-661) VNRX-5133 VX-445 Biohaven Pharmaceutical Holding Co. Ltd. U.S. Department of Health and Human Services VenatoRx Pharmaceuticals Inc. Vertex...
BioCentury | Apr 5, 2019
Company News

Management tracks: Zealand taps Alnylam’s Dulac as CEO, plus ICER, Jnana and more

...the boards of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) and Seattle Genetics Inc. (NASDAQ:SGEN). Infectious diseases company VenatoRx Pharmaceuticals Inc....
...biotech team. Chico was VP of equity research at Raymond James. BioCentury Staff Esteve S.A. JMP Securities Oxford BioDynamics plc VenatoRx Pharmaceuticals Inc. Wedbush...
BioCentury | Apr 1, 2019
Emerging Company Profile

Arixa: Breaking resistance with oral beta lactamase inhibitors

...is an inhibitor of class A and C LACTB that is in Phase I testing. VenatoRx Pharmaceuticals Inc.’s...
...New York, N.Y. Entasis Therapeutics Inc. (NASDAQ:ETTX), Waltham, Mass. Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH), Watertown, Mass. VenatoRx Pharmaceuticals Inc....
BioCentury | Sep 28, 2018
Company News

Everest adds another antibiotic to pipeline through VenatoRx deal

...C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) will receive exclusive rights from VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) to develop...
...China for Antibiotic" ). Eravacyline is approved in the U.S. as Xerava to treat cIAIs. VenatoRx Pharmaceuticals Inc....
BioCentury | Sep 25, 2018
Company News

Everest adds another antibiotic to pipeline through VenatoRx deal

...C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) will receive exclusive rights from VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) to develop...
...Eravacyline is approved in the U.S. as Xerava to treat cIAIs. Elizabeth S. Eaton VNRX-5133 CBC Group Everest Medicines Ltd. VenatoRx Pharmaceuticals Inc. Beta...
BioCentury | Aug 13, 2018
Company News

Management tracks: FDA, Allergan

...Ophthalmology company Ocugen Inc. (Malvern, Pa.) hired James Murphy as CFO. He was CFO at VenatoRx Pharmaceuticals Inc....
BioCentury | Apr 27, 2018
Clinical News

VenatoRx reports preclinical data for VNRX-5133 plus cefepime

...beta lactamase (LACTB) inhibitor. VenatoRx Pharmaceuticals Inc., Malvern, Pa. Product: VNRX-5133 Business: Infectious Indication: Treat bacterial infections Mary Romeo cefepime VNRX-5133 VenatoRx Pharmaceuticals Inc. Beta...
BioCentury | Mar 30, 2018
Finance

Bug money

...pipelines of several VC-backed companies whose leads are more traditional small molecule antibiotics. For instance, VenatoRx Pharmaceuticals Inc....
...S.A., Romainville, France Spero Therapeutics Inc. (NASDAQ:SPRO), Cambridge, Mass. SutroVax Inc., South San Francisco, Calif. VenatoRx Pharmaceuticals Inc....
Items per page:
1 - 10 of 13